Medical Director/Senior Medical Director, Clinical Development

Cullinan Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating potential first- or best-in-class, high-impact therapies for people living with autoimmune diseases and cancer. Founded in 2016, the company has evolved from its oncology roots into a hybrid player with a robust pipeline spanning both autoimmune and cancer indications. Cullinan's diversified portfolio includes clinical-stage assets like CLN-978 for systemic lupus erythematosus and rheumatoid arthritis, CLN-049 for acute myeloid leukemia, and zipalertinib (CLN-081/TAS6417) for EGFR exon 20 insertion NSCLC. The company's approach leverages deep expertise in immune modulation and T cell engagers, established in oncology and now advancing into autoimmune diseases.

With headquarters in Cambridge, Massachusetts, and a workforce of approximately 109 employees, Cullinan operates at the intersection of speed and strategy - deliberately advancing only the most promising molecules to address high unmet medical needs. The company's pipeline reflects a rigorous scientific approach with multiple programs in clinical development, including recent FDA clearance for CLN-978 in lupus and positive Phase 2b data for zipalertinib. Cullinan's mission-driven culture focuses on improving patients' lives by developing therapies that allow people to spend less time managing their conditions and more time on what matters most.